申请人:Sankyo Company Limited
公开号:EP0919232A1
公开(公告)日:1999-06-02
Insulin sensitivity enhancers, such as troglitazone, have the ability to treat and/or prevent hyperuricemia and may thus be used for the therapy or prophylaxis of such diseases as gout, urinary calculus, hyperuricemic nephropathy and Lesch-Nyhan syndrome.
曲格列酮等胰岛素敏感性增强剂具有治疗和/或预防高尿酸血症的能力,因此可用于痛风、尿路结石、高尿酸血症肾病和莱希-尼汉综合征等疾病的治疗或预防。